World Health Organization (WHO). Global Report on Diabetes. 2016. http://www.who.int/diabetes/global-report/en/ Accessed 28 May 2018.
Diabetes UK. Diabetes Prevalence 2017. https://www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2017 Accessed 3 May 2018.
Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98–104.
Article
Google Scholar
Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond). 2015;29(9):1115.
CAS
Article
Google Scholar
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2–3):309–15.
CAS
Article
Google Scholar
Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
Article
Google Scholar
Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corti-costeroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–4.
Article
Google Scholar
PubChem [database on the Internet]. Compound summary for CID 6215. Bethesda: National Center for Biotechnology Information, US Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/fluocinolone_acetonide#section=Top. Accessed May 23, 2018.
Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft AG. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017;31(12):1707–15. https://doi.org/10.1038/eye.2017.125.
CAS
Article
Google Scholar
Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.
Article
Google Scholar
Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–35.
Article
Google Scholar
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.
Article
Google Scholar
Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892–903.
Article
Google Scholar
Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Moreno JR, Dugel P, Lotery A. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015;29(9):1173–80.
CAS
Article
Google Scholar
Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE, FAME Study Group. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging. Retina. 2016;47(5):426–35.
Google Scholar
Parrish RK, Traverso CE, Green K, Dabis RP, FAME Study Group. Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):418–25.
Article
Google Scholar
National Institute for Health and Care Excellence (NICE) guidelines [TA301]; 2013 [online]. https://www.nice.org.uk/guidance/TA301/chapter/1-Guidance. Accessed 29 May 2018.
Alimera Sciences, Inc. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg for diabetic macular edema (DME)—product overview. https://alimerasciences.com/products/iluvien-for-diabetic-macular-edema-dme/. Accessed online 30 May 2018.
Agenzia Italiana del Farmaco. Riclassificazione del medicinale per uso umano « Iluvien » , ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537 (Determina n. 33/2017) (17A00755); 2017 [online]. www.gazzettaufficiale.it/eli/id/2017/02/01/17A00755/sg;jsessionid=rIdm7JHMmJi5EZJXuRAUHw__.ntc-as4-guri2a. Accessed online 17 July 2018.
Alimera Sciences, Inc. Alimera announces the reimbursement of iluvien in Spain [online]. https://www.prnewswire.com/news-releases/alimera-sciences-announces-the-reimbursement-of-iluvien-in-spain-300656891.html. Accessed online 17 July 2018.
Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Therapy. 2015;4(1):51–8.
Article
Google Scholar
Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, Tsaloumas M, Quhill F, Yang Y. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16(1):3.
Article
Google Scholar
Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema. Ophthalmol Therapy. 2016;5(1):95–104.
Article
Google Scholar
Elaraoud I, Quhill H, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (Iluvien®) in patients with diabetic macular edema: 10 eyes with 12 months follow-up. Ophthalmol Therapy. 2016;5(1):105–9.
Article
Google Scholar
Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol (Auckland, NZ). 2016;10:1257.
CAS
Article
Google Scholar
Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond). 2017;31(4):650.
CAS
Article
Google Scholar
Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–72.
Article
Google Scholar
El-Ghrably I, Steel DH, Habib M, Vaideanu-Collins D, Manvikar S, Hillier RJ. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357.
Article
Google Scholar
Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33[Suppl 2]:5–17.
CAS
Article
Google Scholar
Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33[Suppl 2]:19–31.
CAS
Article
Google Scholar
Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33[Suppl 2]:33–43.
Article
Google Scholar
Quhill H, Quhill F. Real-life ILUVIEN (Fluocinolone Acetonide) case study: rapid drying of the macula and improved vision within 2 years after therapy Initiation. Case Rep Ophthalmol. 2016;7(3):579–85.
Article
Google Scholar
Fusi-Rubiano W, Mukherjee C, Lane M, Tsaloumas MD, Glover N, Kidess A, Denniston AK, Palmer HE, Manna A, Morjaria R. Treating diabetic macular oedema (DMO): real world UK clinical outcomes for the 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien™) at 2 years. BMC Ophthalmol. 2018;18(1):62.
Article
Google Scholar
Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53(9):5877–80.
CAS
Article
Google Scholar
Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy. Retina. 2015;35(12):2516–28.
CAS
Article
Google Scholar
Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52(7):4605–9.
CAS
Article
Google Scholar
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–23.
CAS
Article
Google Scholar
Kumar A, Alfahad Q, Mitra A, Elsherbiny S, Lip PL. Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes. Eye (Lond). 2016;30(5):763.
CAS
Article
Google Scholar
Meireles A, Goldsmith C, El-Ghrably I, Erginay A, Habib M, Pessoa B, Coelho J, Patel T, Tadayoni R, Massin P, Atorf J. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye (Lond). 2017;31(5):684–90.
CAS
Article
Google Scholar
Pessoa B, Coelho J, Correia N, Ferreira N, Beirão M, Meireles A. Fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthal Res. 2018;59(2):68–75.
CAS
Article
Google Scholar
Moisseiev E, Morse LS. Fluocinolone acetonide intravitreal implant in the visual axis. JAMA Ophthalmol. 2016;134(9):1067–8.
Article
Google Scholar
Andreatta W, Elaraoud I, Mitra A. Dislogement of fluocinolone acetonide intravitreal implant into the infusion cannula during vitrectomy for retinal detachment. Retinal Cases Brief Rep. 2017. https://doi.org/10.1097/ICB.0000000000000678
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, Dugel PU. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;1(172):72–9.
Article
Google Scholar
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
Article
Google Scholar
Ch’ng SW, Brent AJ, Empeslidis T, Konidaris V, Banerjee S. Real-world cost savings demonstrated by switching patients with refractory diabetic macular edema to intravitreal fluocinolone acetonide (Iluvien): a retrospective cost analysis study. Ophthalmol Therapy. 2017;10:1–8.
Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (ILUVIEN®) versus ranibizumab in the treatment of chronic diabetic macular oedema. Glob Reg Health Technol Assess. 2017; 3(2). https://doi.org/10.5301/grhta.5000268
Article
Google Scholar
Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203.
Article
Google Scholar
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–53.
Article
Google Scholar
Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–46